Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Leukemia Therapeutics Market Forecast: What Value Will The Market Reach By 2030?
The leukemia therapeutics market size has demonstrated strong expansion in recent years. It is anticipated to increase from $18.67 billion in 2025 to $20.14 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.9%. This historical growth can be attributed to elements such as rising leukemia incidence rates, the creation of first-generation chemotherapy drugs, elevated healthcare expenditure in developed regions, advancements in bone marrow transplantation, and an increase in biologics research.
The leukemia therapeutics market size is forecast to show significant expansion in the upcoming years. It is projected to reach $27.41 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. This anticipated growth during the forecast period is influenced by the increasing use of CAR T-cell therapies, the embrace of precision medicine approaches, the incorporation of AI into treatment strategies, the rise in homecare treatment solutions, and the development of new targeted therapies. Noteworthy trends for this period include tailored leukemia treatments, the integration of sophisticated diagnostics, the growth of outpatient and home-based therapies, the advancement of combination treatments, and a strong emphasis on rare and resistant forms of leukemia.
Get A Free Sample Report With In-Depth Market Insights:
Leukemia Therapeutics Market Industry Drivers: What’s Behind The Revenue Growth?
The expanding occurrence of leukemia is propelling the expansion of the leukemia therapeutics market. This condition, leukemia, is a form of blood cancer originating in the bone marrow, characterized by the uncontrolled proliferation of blood cells. Enhanced global access to medical care for leukemia patients, coupled with a wider array of available treatment choices, has led to a heightened demand for leukemia therapeutics. As an illustration, data from a January 2023 report by the American Cancer Society, a US health organization, projects approximately 59,610 new cases of all leukemia types and about 23,710 deaths from all leukemia types in 2023 within the United States. Furthermore, within the same year, projections indicate roughly 20,380 new acute myeloid leukemia (AML) cases and around 11,310 AML-associated fatalities. Consequently, the increasing incidence of leukemia is fostering the development of the leukemia therapeutics market.
Leukemia Therapeutics Market Segment Landscape: Which Areas Lead Development?
The leukemia therapeutics market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments
2) By Type Of Leukemia: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Type Of Leukemia
3) By Molecule Type: Small Molecules, Biologics
4) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Plant Alkaloids, Corticosteroids
2) By Immunotherapy: Monoclonal Antibodies, CAR T-Cell Therapy, Immune Checkpoint Inhibitors, Vaccines
3) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), BCL-2 Inhibitors, IDH Inhibitors, Other Targeted Agents
4) By Other Treatments: Radiation Therapy, Stem Cell Transplantation, Supportive Care Treatments
#Leukemia Therapeutics Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies within the leukemia therapeutics market are innovating products such as CAR T therapies to attract larger customer bases, increase sales, and boost revenue. Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a groundbreaking form of immunotherapy for treating specific types of cancer. For instance, in March 2024, Bristol-Myers Squibb Company, a US-based pharmaceutical entity, announced the US Food and Drug Administration (FDA) approval for Breyanzi (lisocabtagene maraleucel; liso-cel). This therapy is a CD19-directed chimeric antigen receptor (CAR) T cell treatment developed for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undergone at least two prior lines of therapy, including both a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.
Leukemia Therapeutics Market Industry Leaders And Competitive Landscape
Major companies operating in the leukemia therapeutics market are Novartis International AG, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Sanofi S. A., Agios Pharmaceuticals, Amgen Inc., Argenx SE, Astellas Pharma Inc., BioLineRx Ltd., Cellerant Therapeutics Inc., Daiichi Sankyo Company Limited, Forma Therapeutics Inc., Gilead Sciences Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson, Mirati Therapeutics Inc., Molecular Templates Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Seattle Genetics Inc., Stemline Therapeutics Inc., Sunesis Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, TG Therapeutics Inc., Allogene Therapeutics Inc., Blueprint Medicines Corporation, Karyopharm Therapeutics Inc., Verastem Oncology Inc.
View The Full Leukemia Therapeutics Market Report:
Leukemia Therapeutics Market Largest Region By Revenue And Market Share
North America was the largest region in the leukemia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
